LB Pharmaceuticals Common Stock

LBRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$42.99

+$0.52 (+1.22%)

At close: Sep 21, 2026, 4:00 PM ET

$43.11

+$0.12 (+0.28%)

Pre-market: Sep 22, 2026, 8:43 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.23B

Enterprise Value $910.24M

Beta 0.42

Average Volume 283.75K

Shares Outstanding (Diluted) 30.14M

Shares Change YoY 11869.44%

Institutional Ownership 99.89%

Exchange NASDAQ

ISIN US50180M1080

Price Performance

Price Change 1M -11.0%

Price Change 3M 40.5%

Price Change 6M 77.6%

Price Change YTD 110.3%

Price Change 1Y 168.3%

Price Change 3Y 155.9%

Price Change 5Y 155.9%

1M CAGR (ann.) -10.4%

1Y CAGR (ann.) 168.3%

5Y CAGR (ann.) N/A

All-Time CAGR 142.5%

Valuation

PE Ratio -14.47

Forward PE N/A

PEG Ratio -0.08

Forward PEG 1.42

PS Ratio N/A

Forward PS N/A

PB Ratio 3.71

P/FCF Ratio -14.88

P/Adj. FCF Ratio -13.91

P/OCF Ratio -15.75

EV/Sales N/A

EV/EBIT -10.34

EV/EBITDA -10.38

EV/FCF -10.99

Earnings Yield -6.9%

FCF Yield -6.7%

Adj. FCF Yield -7.2%

Financial Health

Net Cash $327.79M

Total Debt $5.22M

Cash & Short-Term Investments $327.79M

Total Assets $361.69M

Current Ratio 15.08

Quick Ratio 15.08

Debt / Equity Ratio 0.02

Debt / EBITDA -0.06

Debt / FCF -0.06

OCF / Debt -15.79

Interest Coverage 0.00

Altman Z-Score 24.73

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -7.0%

Returns

Return on Assets -23.7%

Return on Equity -25.9%

Return on Invested Capital -28.1%

Return on Capital Employed -28.1%

Return on Tangible Assets -23.7%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 5.6%

EPS CAGR 5Y N/A

EPS CAGR 10Y N/A

FCF CAGR 3Y -34.3%

FCF CAGR 5Y N/A

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 3

EPS Growth Next 3Y -18.9%

Revenue Growth Next 3Y N/A

Earnings Date Nov 4, 2026

EPS Estimate (next Q) -$1.63

EPS Growth Est (next Q) 167.2%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $51.86

Price Target Upside 20.6%

Cash Flow

Operating Cash Flow $-82.4M

Free Cash Flow $-82.83M

Adj. Free Cash Flow $-88.61M

FCF Per Share -$2.75

OCF Per Share -$2.73

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-179K

Operating Income $-95.14M

EBITDA $-87.65M

Net Income $-85.69M

EPS (Diluted) -$2.97

Revenue / Employee N/A

Profit / Employee $-1.75M

Employees 49